Bionik Laboratories Reports Q1 Fiscal Year 2018 Financial Results

Bionik Laboratories (OTCQX:BNKL) released their financial and operational results for the first quarter of their fiscal year 2018.
As quoted in the press release:

“We have taken a positive step forward this quarter with the formation of key partnerships and joint ventures. We believe these relationships will enable us to continue the commercialization of our clinical robotic technologies, while also positioning us to enter the homecare medical market in the future with a line of consumer-friendly products,” said Peter Bloch, Chief Executive Officer and Chairman of the Board of Bionik Laboratories Corp. “We will continue to focus on high-growth markets for our technology, such as Asia and the global aging population, as both markets provide significant revenue opportunities for our Company.”
Summary of Financial Results for the Quarter ended June 30, 2017
The Company reported sales of $87,520 for the quarter ended June 30, 2017.
For the quarter ended June 30, 2017, the Company reported a comprehensive loss of $2,245,322, resulting in a loss per share of $0.02, compared to a comprehensive loss of $2,322,772 for the quarter ended June 30, 2016, resulting in loss per share of $0.03.
The Company’s cash and cash equivalents at June 30, 2017 was $846,431 compared to $543,650 at March 31, 2017. Working capital was ($4,937,770) at June 30, 2017 compared to ($4,375,225) at March 31, 2017.

Click here to read the full press release.

Source: www.newswire.ca